Spatially resolved transcriptomics of high-grade serous ovarian carcinoma.
Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK.
iScience. 2022 Feb 14;25(3):103923. doi: 10.1016/j.isci.2022.103923. eCollection 2022 Mar 18.
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ, Espejo Valle-Inclan J, Hami N, Lõhmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H, Kloosterman WP, Cuppen E, Snippert HJG, Zweemer RP, Witteveen PO, Stelloo E.
Cell Rep. 2020 Jun 16;31(11):107762. doi: 10.1016/j.celrep.2020.107762.
The normal menstrual cycle in women.
Mihm M, Gangooly S, Muttukrishna S.
Anim Reprod Sci. 2011 Apr;124(3-4):229-36. doi: 10.1016/j.anireprosci.2010.08.030. Epub 2010 Sep 3.
Patient-derived ovarian cancer organoid carries immune microenvironment and blood vessel keeping high response to cisplatin.
Zhao Y, Wang C, Deng W, Li L, Liu J, Shi Y, Tao X, Zhang J, Cao Q, Cai C, Han X.
MedComm (2020). 2024 Aug 28;5(9):e697. doi: 10.1002/mco2.697. eCollection 2024 Sep.
The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups.
Gat I, Shlush E, Quach K, Librach CL.
Syst Biol Reprod Med. 2015;61(6):336-44. doi: 10.3109/19396368.2015.1089607. Epub 2015 Oct 30.
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A, Zhang C, Austria T, Li YJ, Huang R, Lugo Santiago N, Kohut A, Zhao Q, Borrero RM, Shen B, Cristea M, Wang EW, Song M, Rodriguez-Rodriguez L, Yu H.
J Immunother Cancer. 2024 Apr 5;12(4):e007716. doi: 10.1136/jitc-2023-007716.
Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.
Cavarzerani E, Caligiuri I, Bartoletti M, Corona G, Perin T, Palumbo A, Ditto A, Occhiali T, Canzonieri V, Rizzolio F.
J Adv Res. 2025 Aug 7:S2090-1232(25)00598-3. doi: 10.1016/j.jare.2025.08.009. Online ahead of print.
New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
Torkildsen CF, Austdal M, Jarmund AH, Kleinmanns K, Lamark EK, Nilsen EB, Stefansson I, Sande RK, Iversen AC, Thomsen LCV, Bjørge L.
Front Immunol. 2024 Jun 14;15:1394497. doi: 10.3389/fimmu.2024.1394497. eCollection 2024.
The best ovarian reserve marker to predict ovarian response following controlled ovarian hyperstimulation: a systematic review and meta-analysis.
Salemi F, Jambarsang S, Kheirkhah A, Salehi-Abargouei A, Ahmadnia Z, Hosseini HA, Lotfi M, Amer S.
Syst Rev. 2024 Dec 18;13(1):303. doi: 10.1186/s13643-024-02684-0.
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine.
Cappuccio S, Distefano MG, Ghizzoni V, Fagotti A, Scambia G.
Gynecol Oncol Rep. 2020 Feb 13;32:100547. doi: 10.1016/j.gore.2020.100547. eCollection 2020 May.
